Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy-Only Conditioning for T-Cell Depleted HSCT
NCT00582933Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2001
- Primary completion
- Apr 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, melphalan, fludarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2001; status: completed.
02
Drugs
busulfanmelphalanfludarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00582933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582933.